GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects a multi-blockbuster ...

Nammi Therapeutics begins patient dosing in phase 1 study of QXL138AM for advanced solid tumours and multiple myeloma: Los Angeles Monday, November 11, 2024, 13:00 Hrs [IST] Nammi ...

Nammi Therapeutics has commenced the first in-human Phase I trial of QXL138AM by dosing the first subject for treating advanced solid tumours and multiple myeloma. The dosing was conducted at The ...

Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced groundbreaking research findings demonstrating the potential of its AI to ...

SystImmune, Inc (SystImmune), a clinical-stage biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for BL-M17D1 ...

president and chief executive officer of C4 Therapeutics.“We look forward to continuing this momentum with cemsidomide Phase 1 data in multiple myeloma and in non-Hodgkin's lymphoma being ...

Background: Autologous stem cell transplantation (autoSCT) has an important role in the treatment of patients with symptomatic multiple myeloma (MM). Treatment options for myeloma have expanded in ...

Currently it is in Phase III stage of clinical trial evaluation to treat Refractory Multiple Myeloma. RAPA-201: Rapa Therapeutics RAPA-201 It is a type of autologous cell therapy. The drug ...

Historically, we evaluated myeloma through monoclonal proteins or free light chains in the blood and urine and percentage of plasma cells in the bone marrow. But this is like the iceberg ...

LONDON and BOSTON, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the ...

Revlimid (lenalidomide) is a brand-name oral capsule prescribed to treat multiple myeloma and certain other blood cell cancers in adults. This article covers topics such as side effects ...